Microglial dysfunction has been proposed as one of the many cellular mechanisms that can contribute to the development of Alzheimer's disease (AD). Here, using a transcriptional network map of the human frontal cortex, we identify five gene modules of co-expressed genes related to microglia and assess their role in the neuropathologic features of AD in 541 subjects from two cohort studies of brain aging. Two of these transcriptional programs -modules 113 and 114 -relate to the accumulation of β -amyloid, while module 5 relates to tau pathology.
Introduction
Alzheimer's disease (AD) is characterized pathologically by the accumulation of both β -amyloid and tau pathologies which lead to the gradual loss of cognitive function and, ultimately, dementia 1 . The amount of these two pathologies that is present in the older brain is strongly but only partially correlated 2 , enabling us to distinguish molecular pathways that are involved in one or the other process. While genome-wide association studies have unequivocally pointed to the innate immune system and particularly myeloid cells as major contributors to AD pathophysiology 3-5 , our current understanding of the mechanistic involvement of microglia and infiltrating macrophage in human AD pathology is rudimentary as it is largely based on studies performed in animal models of AD, which imperfectly capture aspects of human disease.
Myeloid cells have been implicated in all aspects of AD, from the asymptomatic phase of amyloid accumulation to the progression of dementia, but there is little clarity on how disparate human observations can be assembled into a coherent picture. Therefore, to identify the different components of human myeloid responses that exist in the neocortex and to examine how each component contributes to the continuum of AD-related pathological and clinical traits in the aging brain, we evaluated a recently derived Molecular Network Map of the aging human frontal cortex using tissue level RNA sequence (RNAseq) data obtained from the frozen dorsolateral prefrontal cortex of participants in two prospective studies of cognitive aging, the Religious Order Study (ROS) and the Memory Aging Project (MAP) [6] [7] [8] . From the RNAseq data, we derive groups of co-expressed genes -that we term "modules" -and build the network from these modules as well as outcome measures available from each of the 541 participants that were profiled. As these individuals are non-demented at study entry, they represent a sampling of the older, aging population. At the time of death, they display a full spectrum of clinicopathologic features related to AD that are found in older people including cognitive decline, dementia, extracellular β-amyloid deposition, hyperphosphorylation of tau, and microglial activation 6, 7, 9 .
Here, using our recently established gene expression signature of aged human microglia 10 , we identify five microglia-related gene co-expression modules that capture different transcriptional programs of microglia. We focus on dissecting the role of these modules in AD; in mapping the conditional relationship between modules and cognitive and neuropathologic outcomes, we identify and validate a microglial module that contributes to the accumulation of tau pathology.
Two other modules relate to β -amyloid, and a fourth -enriched for LOAD susceptibility genesappears to be primarily related to aging. Thus, we provide an initial immune network perspective of the divergent sets of co-expressed genes that govern microglia identity in the aging human brain and identify the relationship of these components to specific pathologies.
Results
A molecular network map derived from RNA sequence data ROS and MAP are two large longitudinal studies of aging that were designed and are managed by the same group of investigators so that their data can be merged in joint analyses 11, 12 .
Participants are non-demented at study entry, agree to brain donation at the time of death, and are evaluated annually with a battery of 21 neuropsychologic tests. A person-specific slope of cognitive decline is calculated for each participant based on 17 tests in common 6, 7 .
Demographic and clinical characteristics of the 541 participants used in these analyses are presented in Supplementary Table 1 .
To reduce the dimensionality of the RNAseq data generated from the DLPFC (Dorsolateral Prefrontal Cortex) of each subject, we previously defined modules of co-expressed genes using the Speakeasy algorithm 13 : there are 47 such modules that contain a minimum of 20 genes and a median of 331 genes. Thus, each module contains a group of genes that have a shared regulatory architecture, and the 47 modules represent the nodes of our network 8 .
Identifying microglia-related modules
In this manuscript, we take a deeper look at the subset of these modules that capture the role of microglia. We identified modules enriched for microglial genes as defined in a new reference RNAseq data set derived from live, purified human microglia/macrophages extracted from fresh autopsy DLPFC samples of 10 ROSMAP participants of advanced age: the HuMi_Aged gene set consists of 1,081 microglia enriched genes that were identified based on a four-fold increase in expression in microglia vs. DLPFC expression 10 .
Of the 47 modules, five are enriched (p<0.0011) for the HuMi_Aged gene set: modules m5, m113, m114, m115, and m116 (Table 1, Figure 1, Supplementary Figure 1) . Results are similar if we use other human microglial profiles 14 . To determine whether these enriched modules are specific to microglia, we performed a similar enrichment analysis using reference RNAseq profiles of human iPSC-derived neurons and primary human astrocytes (https://www.synapse.org/#!Synapse:syn2580853/wiki/409840). Of the five modules enriched for microglial genes, none are enriched for neuronal genes, but two modules (m113 and m115) are also enriched for astrocyte genes (Supplementary Table 2 ). The latter modules may relate to immune responses shared with astrocytes, which are well-known to contribute to central nervous system inflammatory responses 15 . By contrast, m5, m114 and m116 appear unique to microglia, with m116 displaying, by far, the greatest microglial enrichment: 67% of its 224 genes are present in our list of 1081 microglial genes. It contains many well-known myeloid/microglial genes such as TREM2 and TYROBP. This result is emphasized in a parallel enrichment analysis of microglial, neuronal and astrocytic profiles generated from mouse brain 16 where we observe that m116 is the most cell-type specific of all tested modules (Supplementary Figure   2) . Given the strength of its enrichment for genes that are reported to be microglial, m116
probably represents a set of genes expressed by all microglia. We note that m116 captures the same set of coexpressed genes that led to the report on the role of TYROBP in AD 4 .
In our original evaluation of neocortical modules 8 , these five microglial modules were all robust:
the component genes of each module (see Supplementary Table 3 Figure 3) suggesting that each module may be maintained by an exclusive set of regulatory mechanisms.
We previously reported that m116 is enriched in AD susceptibility genes 18 (Supplementary 
Modules diverge in their association with AD pathologies
To resolve the relative roles of the different modules in different aspects of AD, we determined their relation to the rich clinicoalpathologic phenotypes available in ROSMAP participants using a meta-feature calculated for each of the five modules. In Table 2 To replicate these associations, we used an existing dataset of frontal cortex data from subjects with AD and subjects without AD and imposed our module definitions on their data 4 ; since our quantitative measures of AD neuropathology are not available in these subjects, we replicate the association of modules m5 and m114 with a pathologic diagnosis of AD. Both m5 (p=5.05×10 -5 ) and m114 (p=1.13×10 -4 ) replicate in this repurposed case/control dataset derived from brain bank samples. In a second level of replication and to address the issue of whether some of these associations may be detectable at the epigenetic level as well, we imposed our module definitions on H3K9Ac (a marker of active promoters) ChIPseq data available on 669
ROSMAP subjects, and we found that all of the previously observed associations are also found at this level, with the exception of m116 and age (Supplementary Table 7) .
Assessing the microglial sub-network within the neocortex AD-related traits are correlated to one another (Supplementary Figure 4) 7×10 -30 ). This result suggests that either the number or proportion of microglia in the neocortex (best captured by m116) is higher with age or that the expression of this set of genes is higher with age. The latter of these two hypotheses seems to be most likely as this m116:age association did not replicate in the H3K9Ac ChIPseq data, despite its strong effect size in the RNA data. So, while m116 is not directly related to the pathology measures or to cognitive decline, the overexpression of these genes in microglia of older individuals could contribute to the mechanisms behind aging, which is the single greatest risk factor for AD.
Looking at the other modules, we find that three are associated with pathologic measures; however, we begin to find distinct dissociations between β -amyloid (m113 and m114) and tau (m5) burden. m113 and m114 appear to be independently associated with β -amyloid pathology which typically accumulates early in the asymptomatic and early symptomatic phase of AD, and they are not directly associated with tau pathology. On the other hand, m5 is associated with the burden of tau pathology in an β -amyloid-independent manner (Figure 2a and 2b) .
To begin to understand the magnitude of the effect of m5 and m114 on AD traits and to infer the most likely direction of the associations based on our cross-sectional data, we performed mediation analysis. Since cognitive decline, m114 and In parallel, we evaluated m5 whose association with tau is very intriguing. When we add m5 to a model assessing the effect of sex on tau burden, we see that the effect of sex is diminished by 17%, suggesting that m5 may mediate part of the effect of sex on tau accumulation since sex determination occurs before the accumulation of late life pathologies. However, we highlight that m5 remains significantly associated with tau pathology after accounting for the effect of sex (p=1.58×10 -6 ) (Figures 2a), so it must also be reflecting the effects of other mechanisms. To explore the possible sequence of events among m5 expression, cognitive decline and tau pathology, we performed a second mediation analysis which suggests that m5 expression precedes tau accumulation and its effect on cognitive decline may thus be mediated through the accumulation of tau pathology (Figure 2c) . These results are consistent with previously described the putative role of microglia in a mouse model of tau pathology 20 .
Role of m5 in the aging neocortex
Since m5 is distinct from m116 in the correlation structure of our RNAseq data but still very enriched for genes found in aged human microglia, we hypothesized that it may capture a subset of microglia with a particular function. We therefore turned to a phenotype that we had previously captured in our subjects 21 : the proportion of microglia with an activated stage III morphology based on immunohistochemical studies (Figure 3a) . This neuropathologic measure is available in 104 subjects who also have RNAseq data. We observe a strong association between the expression of m5 and the proportion of microglia which are categorized Figure 3c ). Our modeling suggests that VASP should be expressed in microglia and should be expressed at higher level in microglia that have a morphology consistent with activation according to standard neuropathologic assessment (i.e.
have a more globular, stage III morphology).
VASP has not been explicitly reported to be expressed in microglia previously, and so we first demonstrated that it is expressed in cells labeled with TMEM119, a protein proposed as a panmicroglial marker not expressed on infiltrating macrophages 22 (Figure 4a) . Interestingly, only a subset of TMEM119+ microglia are VASP+. While VASP is reportedly expressed in human microglia 16 , it is also found to be expressed in fetal human astrocytes and to a much lesser extent in other cells of the CNS parenchyma. As shown in Figure 4b , we found VASP to be expressed in microglia in the vicinity of neuritic plaques, that consist of deposits of both β -amyloid and tau fibrils.
To evaluate whether, as the m5 analyses suggest, VASP is a marker of activated microglia, we used automated image analysis 23 to assess whether the subset of TMEM119+ cells that were also VASP+ had an activated morphology. To minimize bias, we used Cell Profiler to identify individual TMEM119+ cells and then captured (1) to be similar among the limited number of pathologically defined AD subjects (n=4) and subjects with no cognitive impairment (n=3). Overall, these analyses confirm that m5, as estimated by its proxy marker VASP, is more highly expressed in morphologically activated microglial cells and that the TMEM119+VASP+ cells are found in the vicinity of tau pathology.
Discussion
We performed a detailed in silico dissection of five cortical transcriptional modules of human microglia in the aging human brain and discovered that they relate to different functional responses of microglia. In particular, we differentiated the role of m116 as a module reflecting microglial aging from those of m113 and m114 that are involved in promoting the accumulation of β -amyloid and of m5 that captures a morphologically-activated microglial state that contributes to the accumulation of tau. Thus, we begin to empirically differentiate groups of microglial genes that work together to accomplish specific, distinct functions. This regulatory architecture is present at the chromatin level: our H3K9Ac data both confirms the correlation of genes within RNAseq-defined modules and validates their association with AD-related traits.
Importantly, given our large sample size, we can identify different modules involved in β -amyloid and tau pathology. Our analyses suggest the existence of multiple microglial functional modules active in parallel within the same brain. In the case of m5, we pushed validation efforts further to confirm, in situ, the hypothesis that it reflects the presence of a subset of microglia that are more activated and found in the vicinity of neuritic plaques which contain tau fibrils in addition to amyloid. Diffuse plaques do not show this aggregation of activated microglia. Our data therefore implicate microglia in both β -amyloid and tau accumulation, and the three distinct transcriptional modules (m5, m113, and m114) are all present in the brain of aged individuals. This observation highlights the complexity that we face in developing immunomodulatory therapies for AD: they will have to be tuned to specifically engage or shut down a given transcriptional module while not exacerbating the ongoing perturbation of others. In the case of tau, we propose that the increased prevalence of activated microglia leads to more tau accumulation, suggesting that downregulation of this module may be a therapeutic option. The relatively specific enrichment of the JUN kinase pathway in m5 suggests that it may be regulated in a manner that is somewhat distinct from the other four modules and could provide a relatively specific target for drug development.
A surprising result is the lack of strong association between m116 and β -amyloid or tau: it is contrary to a simple narrative that this module, enriched for AD susceptibility genes from GWAS, exerts its effect primarily through increased accumulation of the neuropathologies that define AD.
Β
-amyloid and tau burden only explain some of the variance of cognitive decline and AD dementia 9 , and our m116 results suggest that microglia may be involved in AD through mechanisms that remain elusive today. We clearly demonstrate the presence of an effect of aging on microglia, but this effect does not translate directly into pathology in our analysis. One thing to appreciate is that many AD GWAS often use samples of convenience as control subjects: these subjects are only coarsely characterized. Further, since AD incidence increases with advancing age, the majority of control subjects are likely to develop AD if they live long enough. Thus, the AD GWAS may have uncovered genes that have a strong effect on advancing the age of onset of AD and emerge as susceptibility genes because of the study design. Such an effect would tie in with our results where TREM2, INPP5D, and other genes in m116 are associated primarily with microglial aging.
One possibility is that the different transcriptional modules described here correspond to different microglia subpopulations. Given their sentinel and effector nature, the diversification of microglia phenotypes in specialized niches in the aged brain parenchyma burdened with β -amyloid and tau deposits is indeed a likely scenario. A longstanding observation is the morphological transformation of parenchymal microglia cells in and around the plaques in AD.
Nonetheless, until now the molecular identity of the plaque associated (ameboid or stage III) activated microglia was obscure. This study takes the first steps to assign, though in an indirect way, a transcriptomic signature to a morphologically defined subpopulation of microglia. Future studies now in progress that utilize single cell RNA-sequencing approaches will allow us to understand how the transcriptional modules described here are represented in the population structure of microglia in the aged and AD human brain and what is the relationship of the subpopulations with clinical and histopathological features.
Nonetheless, our study has certain limitations; foremost amongst these is the fact that our pathologic measures are cross-sectional since they are obtained at autopsy. We therefore cannot comment on causality or on the exact sequence of events that is occurring in the human brain; mouse studies or in vivo microglial imaging will be necessary to help resolve such questions. Further, this neuroimmune network map should be seen as a first draft: microglia represent a minority of the cells found in the human cortex and have a relatively low quantity of mRNA in their cytoplasm. Thus, the level of expression of microglial genes, particularly those present only in a subset of microglia is likely to be underestimated or even absent from the tissue level data (e.g. CD33). Second generation maps derived from isolated microglia and single microglia transcriptional profiles will be essential to better understand the involvement of microglia in the pathophysiology of AD and the complex architecture of microglial subsets in the aged and AD brain.
Overall, we have generated an initial framework on which we and others can assemble additional data from in vivo and in vitro experimental models: when perturbing a particular gene of interest, we have to be cognizant of its membership to a given module and to the effect of such perturbations on different transcriptional programs found in microglia that may not be directly measured in an experimental system. The immune system is exquisitely modulated by a complex set of checks and balances in which AD genes such as CD33, TREM1, and TREM2 are contributing to regulate the level of activation 24 , and, as seen in other immune functional programs, small differences in the level of receptor engagement or the presence of costimulatory molecules can result in dramatically different responses that can sometimes be the opposite of an anticipated response. By refining the set of microglial genes implicated in β -amyloid vs. tau pathology, we mark a big step forward in better targeting drug development programs both by proposing new targets and by defining novel outcome measures that can be used to assess the functional consequences of lead compounds.
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Figures Figure 1 -Identification of microglia related genes and modules
The expression (FPKM) of genes in bulk DLPFC tissue are compared to their expression in isolated microglia. We highlight microglia related genes in blue, these genes have a 4-fold higher expression in isolated microglia compared to bulk tissue are likely involved in processes that are relatively specific to microglia. The genes in module 116 are highlighted in gray and mostly appear to be more highly expressed in isolated microglia compared to bulk tissue. Online methods
ROSMAP cohort
The subjects profiled in this study are participants in one of two prospective cohort studies of aging, the Religious Orders Study (ROS) 6 and the Memory and Aging Project (MAP) 7 which are designed to be merged for joint analyses. These studies enroll non-demented individuals and include detailed, annual ante-mortem characterization of each subject's cognitive status as well as prospective brain collection and a structured neuropathologic examination at the time of The RNA-Seq data was processed by our parallelized pipeline. This pipeline includes trimming the beginning and ending bases from each read, identifying and trimming adapter sequences from reads, detecting and removing rRNA reads, and aligning reads to reference genome. The 
Neuritic plaques and Neurofibrillary tangles
Neuritic plaque burden and Neurofibrillary tangle burden was determined by microscopic examination of silver-stained slides from 5 regions: midfrontal cortex, midtemporal cortex, inferior parietal cortex, entorhinal cortex, and hippocampus. The count of each region is scaled by dividing by the corresponding standard deviation. The 5 scaled regional measures are then averaged to obtain a summary measure for both neuritic plaque and Neurofibrillary tangle burden.
Cognitive Decline
The ROS and MAP methods of assessing cognition have been extensively summarized in previous publications [33] [34] [35] [36] [37] . Uniform structured clinical evaluations, including a comprehensive cognitive assessment, are administered annually to the ROS and MAP participants. Scores from 17 cognitive performance tests common in both studies were used to obtain a summary measure for global cognition as well as measures for five cognitive domains of episodic memory, visuospatial ability, perceptual speed, semantic memory, and working memory. The summary measure for global cognition is calculated by averaging the standardized scores of the 17 tests, and the summary measure for each domain is calculated similarly by averaging the standardized scores of the tests specific to that domain. To obtain a measurement of cognitive decline, the annual global cognitive scores are modeled longitudinally with a mixed effects model, adjusting for age, sex and education, providing person specific random slopes of decline. The random slope of each subject captures the individual rate of cognitive decline after adjusting for age, sex, and education. Further details of the statistical methodology have been previously described 38 .
Microglia morphology
Immunohistochemistry for microglia was performed using an Automated Leica Bond 
Definition of Microglia genes
An aged human microglia signature (HuMiAged gene set) of 1081 microglia related genes were defined by comparing the expression of genes in DLPFC isolated microglia to their expression level in the bulk DLPFC tissue. The identified genes had four-fold larger expression in the microglia samples relative to the tissue level samples and average FPKM greater than one in the microglia samples. These microglia related genes can be viewed in the microglia vs bulk space in Figure 1 .
Definition of modules from ROSMAP
The SpeakEasy algorithm 39 was used to derive gene modules from normalized gene expression data. Consensus clustering results from 100 initializations of the SE algorithm yielded 257 modules, 47 of which contained at least 20 gene members (meaning modules are assigned for 98% of genes) and were examined in downstream analyses. Pseudo-expression values for each module were calculated by taking the mean expression level of all genes assigned to that module after the expression data has been standardized for each gene.
Modules enriched for microglia genes
A series of hypergeometric tests were used to test whether modules contained more microglia related genes than expected by chance. All 13153 genes that had FPKM greater than 1 in the tissue level samples were used as the background universe for the tests.
Pathway analysis of modules
A series of hypergeometric tests were used to test whether modules contained more genes in any of the Gene Ontology biological process processes 40 than expected by chance. Only biological processes with more than 20 annotated genes or less than 500 genes were tested.
Genes that were both in at least one biological process and module were used as the background universe for the tests.
GWAS hits

IGAP enrichment
A series of hypergeometric tests were used to test whether modules contained more genes with at least one probe that was 50KB up or down-stream of the gene that was one nominally significant probe in IGAP 18 than expected by chance. Genes that were in the module definition and contained at least one IGAP probe were used as the background universe for the tests.
Associations with Alzheimer's related traits.
Testing association with traits
Simple linear regression analysis was used to associate either gene expression or average module expression to several variables that measured the neuro-pathology in the AD brain and cognitive decline. These included either the numbers of neuritic plaques (NP), neurofibrillary tangles (NFT), the amount of β -amyloid or tau and the rate of cognitive decline (cogDec). All the associations were adjusted for age, sex, study (ROS or MAP), RNA Integrity number (RIN) and post-mortem interval (PMI).
Replication of association in Zhang et al.
We replicated the association of the immune modules with Alzheimer's disease pathology in an independent microarray gene expression data from cortex (DLPFC) from a previous study by Zhang and colleagues 41 . Data was downloaded from GEO with accession number GSE44772.
The expression data was quantile normalized and corrected for age, gender, post-mortem interval, pH, RIN and batch. Simple linear regression was then used to test for association with diagnosis of Alzheimer's disease.
Partial correlation analysis
Partial correlations were used to further disentangle the highly correlated modules and traits. A partial correlation between a trait and a module is the correlation between the trait and module after accounting of the behavior of all other traits and modules. Graphical lasso 42 was used to set small partial correlations to zero and was tuned using repeated 10-fold cross-validation to estimate the penalty parameter.
Activated microglia validation
Six μ m sections of formalin-fixed paraffin-embedded tissue from the DLPFC were used to stain TMEM119 (Sigma Aldrich), VASP (Santa Cruz Biotech) and β -amyloid 1-42 (Biolegend).
Immunohistochemistry was performed using citrate as antigen retrieval. The sections are blocked with blocking medium (8% of horse serum and 3% of BSA) and incubated overnight at 
